FDA’s 2026 Draft Guidance on Mandatory Cosmetic Recall Authority

Introduction: A New Enforcement Era for Cosmetics

For decades, the cosmetics industry operated under a voluntary recall paradigm. If a product posed a safety concern, the Food and Drug Administration could request a recall, issue public warnings, or pursue seizure and injunction actions—but it lacked the unilateral authority to compel a company to pull a product from the market. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) fundamentally altered that landscape by granting FDA mandatory recall authority over cosmetic products for the first time in the agency's history.

FDA's 2026 draft guidance represents the agency's most detailed articulation to date of how it intends to exercise this authority. For Responsible Persons—manufacturers, packers, and distributors whose names appear on cosmetic labels—the guidance signals a meaningful shift in regulatory risk exposure, one that warrants immediate attention from in-house counsel, quality assurance teams, and executive leadership alike.

The Statutory Foundation: MoCRA's Mandatory Recall Authority

MoCRA's recall provisions were deliberately modeled on the mandatory recall framework Congress created for food products under the FDA Food Safety Modernization Act. The statutory architecture generally follows a sequential process:

• FDA must first determine there is a reasonable probability that a cosmetic product is adulterated or misbranded, and that use of or exposure to the product will cause serious adverse health consequences or death.
• FDA is required to first request that the Responsible Person voluntarily cease distribution and recall the product.
• If the Responsible Person refuses or fails to act within the time specified, FDA may order cessation of distribution and, following an opportunity for an informal hearing, issue a mandatory recall order.

This graduated structure is designed to preserve a degree of procedural fairness while still giving FDA a credible enforcement backstop. The 2026 draft guidance does not alter this statutory sequence—Congress, not FDA, controls that architecture—but it does attempt to clarify how FDA will apply the standard in practice.

What the Draft Guidance Proposes

The draft guidance focuses heavily on the operational and evidentiary dimensions of the recall process, including:

• Criteria for "serious adverse health consequences." The guidance offers illustrative examples of the types of contamination, mislabeling, and formulation defects FDA views as meeting the threshold for mandatory action, including microbial contamination, undisclosed allergens, and certain unapproved color additives.
• Timelines for voluntary compliance. The guidance proposes expectations around how quickly a Responsible Person must respond to FDA's initial recall request before the agency considers escalation to a cessation order.
• Documentation expectations. FDA signals that it will closely scrutinize a company's internal investigation records, adverse event reports, and safety substantiation files when evaluating whether a recall is warranted.
• Coordination with recall classification. The guidance addresses how FDA intends to align mandatory cosmetic recalls with its existing Class I, II, and III recall classification system, which affects public messaging and the urgency communicated to consumers and retailers.

Because this remains draft guidance, it is non-binding and subject to revision following the public comment period. Nevertheless, it provides the clearest window yet into FDA's enforcement priorities and should inform compliance planning now, rather than after finalization.

Key Legal and Compliance Risks for Responsible Persons

The shift from voluntary to mandatory recall authority carries several distinct risks:

• Reputational exposure. A mandatory recall order is a public, FDA-driven event, carrying different market and media implications than a company-initiated voluntary recall.
• Litigation exposure. Mandatory recalls often generate parallel consumer protection and product liability claims, and plaintiffs' counsel frequently cite FDA recall orders as evidence of defect or negligence.
• Operational disruption. Cessation-of-distribution orders can immediately halt sales, affecting revenue, retailer relationships, and inventory management.
• Downstream contractual consequences. Supply agreements, insurance policies, and indemnification provisions may be triggered by a mandatory recall in ways that differ from voluntary action.

Procedural Due Process Considerations

Responsible Persons retain meaningful procedural rights within this framework, and the draft guidance should be read with those protections in mind. The right to an informal hearing before a mandatory recall order issues is a critical checkpoint. Companies should treat this hearing opportunity not as a formality, but as a substantive opportunity to present root-cause analysis, corrective action plans, and scientific data challenging FDA's risk assessment.

Counsel should also evaluate whether FDA's underlying risk determination is adequately supported by the administrative record, as this may become relevant in any subsequent judicial review of agency action.

Actionable Compliance Strategies

Given the direction of the draft guidance, Responsible Persons should consider the following steps now:

• Stress-test recall readiness. Maintain an up-to-date, tested recall plan that includes lot-level traceability, distribution records, and a designated crisis response team.
• Strengthen safety substantiation files. Ensure product safety documentation is current, scientifically defensible, and readily retrievable in the event of an FDA inquiry.
• Audit adverse event reporting processes. Confirm that serious adverse event reports are being captured, documented, and reported in accordance with MoCRA's timelines.
• Engage counsel early. Involve regulatory counsel at the first sign of an FDA inquiry, well before a formal recall request is issued, to preserve negotiating leverage and procedural rights.
• Prepare for the informal hearing. Develop internal protocols for rapidly assembling scientific and operational evidence to support a company's position at any hearing.
• Monitor the guidance's finalization. Submit comments where appropriate and track changes between the draft and final guidance, as FDA's final enforcement posture may shift based on industry input.

The Interplay Between Voluntary and Mandatory Recalls

One of the more subtle implications of the draft guidance is its effect on voluntary recall decision-making. Companies may now face pressure to initiate voluntary recalls more quickly and proactively, rather than risk FDA concluding that a voluntary request would be refused or delayed. In this sense, the mandatory recall authority functions as a background incentive shaping voluntary compliance behavior, even in cases where FDA never formally exercises its mandatory powers.

Looking Ahead

FDA's 2026 draft guidance is a significant marker in the maturation of cosmetics regulation under MoCRA. While the guidance remains subject to change, the underlying statutory authority is firmly established, and the direction of FDA's enforcement thinking is unlikely to reverse. Responsible Persons that treat recall readiness as a core compliance function—rather than a reactive exercise—will be best positioned to manage both the legal and business risks this new regulatory environment presents.